Stock Price, News, Quote and Profile of LONGEVERON INC-A(NASDAQ:LGVN) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

LONGEVERON INC-A

NASDAQ:LGVN (4/19/2024, 7:01:19 PM)

After market: 1.9796 +0.06 (+3.1%)

1.92

-0.09 (-4.48%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap4.82M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Longeveron, Inc. is a clinical stage biotechnology company. The company is headquartered in Miami, Florida and currently employs 19 full-time employees. The company went IPO on 2021-02-12. The firm's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The firm is primarily focused on three pipeline indications, such as aging related frailty, Alzheimer's disease (AD), acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The firm has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Company Info

LONGEVERON INC-A

1951 NW 7th Ave, Ste 520

Miami FLORIDA 33136

P: 13053027158

CEO: Geoff Green

Employees: 19

Website: https://www.longeveron.com/

LGVN News

2 days ago - LongeveronLongeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering

Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering....

3 days ago - ChartmillTop movers in Wednesday's session

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

3 days ago - ChartmillWhich stocks are experiencing notable movement on Wednesday?

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.